{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T07:05:08Z","timestamp":1769065508239,"version":"3.49.0"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:00:00Z","timestamp":1387324800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2013,12,18]],"date-time":"2013-12-18T00:00:00Z","timestamp":1387324800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Invest New Drugs"],"published-print":{"date-parts":[[2014,8]]},"DOI":"10.1007\/s10637-013-0049-2","type":"journal-article","created":{"date-parts":[[2013,12,17]],"date-time":"2013-12-17T03:03:03Z","timestamp":1387249383000},"page":"774-782","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":20,"title":["Dysphonia induced by anti-angiogenic compounds"],"prefix":"10.1007","volume":"32","author":[{"given":"Erika","family":"Saavedra","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antoine","family":"Hollebecque","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Charles","family":"Soria","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dana M.","family":"Hartl","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,12,18]]},"reference":[{"issue":"21","key":"49_CR1","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1056\/NEJM197111182852108","volume":"285","author":"J Folkman","year":"1971","unstructured":"Folkman J (1971) Tumor angiogenesis: therapeutic implications. N Engl J Med 285(21):1182\u20131186","journal-title":"N Engl J Med"},{"issue":"21","key":"49_CR2","doi-asserted-by":"publisher","first-page":"4368","DOI":"10.1200\/JCO.2002.10.088","volume":"20","author":"HF Dvorak","year":"2002","unstructured":"Dvorak HF (2002) Vascular permeability factor\/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 20(21):4368\u20134380","journal-title":"J Clin Oncol"},{"issue":"19","key":"49_CR3","doi-asserted-by":"publisher","first-page":"2039","DOI":"10.1056\/NEJMra0706596","volume":"358","author":"RS Kerbel","year":"2008","unstructured":"Kerbel RS (2008) Tumor angiogenesis. N Engl J Med 358(19):2039\u20132049","journal-title":"N Engl J Med"},{"key":"49_CR4","unstructured":"\u201cCancer: principles & practice of oncology: primer of the molecular biology of cancer.\u201d [Online]. Available: http:\/\/solution.lww.com\/cancermolecularbiology. [Accessed: 12-May-2013]"},{"issue":"4587","key":"49_CR5","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1126\/science.6823562","volume":"219","author":"DR Senger","year":"1983","unstructured":"Senger DR, Galli SJ, Dvorak AM, Perruzzi CA, Harvey VS, Dvorak HF (1983) Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science (New York, NY) 219(4587):983\u2013985","journal-title":"Science (New York, N.Y.)"},{"issue":"4935","key":"49_CR6","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1126\/science.2479986","volume":"246","author":"DW Leung","year":"1989","unstructured":"Leung DW, Cachianes G, Kuang WJ, Goeddel DV, Ferrara N (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science (New York, NY) 246(4935):1306\u20131309","journal-title":"Science (New York, N.Y.)"},{"key":"49_CR7","doi-asserted-by":"crossref","unstructured":"Bergers G, Benjamin LE (2003) Tumorigenesis and the angiogenic switch. Nat Rev Cancer (no. 6):401\u201310","DOI":"10.1038\/nrc1093"},{"issue":"1","key":"49_CR8","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1634\/theoncologist.2008-0213","volume":"14","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Yi J, Ince W, Novotny WF, Rosen O (2009) The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 14(1):22\u201328","journal-title":"Oncologist"},{"key":"49_CR9","doi-asserted-by":"publisher","first-page":"S62","DOI":"10.3816\/CCC.2004.s.010","volume":"4","author":"H Hurwitz","year":"2004","unstructured":"Hurwitz H (2004) Integrating the anti\u2013VEGF-A humanized monoclonal antibody bevacizumab with chemotherapy in advanced colorectal cancer. Clin Colorectal Cancer 4:S62\u2013S68","journal-title":"Clin Colorectal Cancer"},{"issue":"12","key":"49_CR10","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1200\/JCO.2007.14.9930","volume":"26","author":"LB Saltz","year":"2008","unstructured":"Saltz LB, Clarke S, D\u00edaz-Rubio E, Scheithauer W, Figer A, Wong R, Koski S, Lichinitser M, Yang T-S, Rivera F, Couture F, Sirz\u00e9n F, Cassidy J (2008) Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized phase III study. J Clin Oncol Off J Am Soc Clin Oncol 26(12):2013\u20132019","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"49_CR11","doi-asserted-by":"publisher","first-page":"2184","DOI":"10.1200\/JCO.2004.11.022","volume":"22","author":"DH Johnson","year":"2004","unstructured":"Johnson DH, Fehrenbacher L, Novotny WF, Herbst RS, Nemunaitis JJ, Jablons DM, Langer CJ, DeVore RF, Gaudreault J, Damico LA, Holmgren E, Kabbinavar F (2004) Randomized phase II trial comparing bevacizumab plus carboplatin and paclitaxel with carboplatin and paclitaxel alone in previously untreated locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 22(11):2184\u20132191","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9605","key":"49_CR12","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1016\/S0140-6736(07)61904-7","volume":"370","author":"B Escudier","year":"2007","unstructured":"Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay J-O, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103\u20132111","journal-title":"Lancet"},{"issue":"28","key":"49_CR13","doi-asserted-by":"publisher","first-page":"4733","DOI":"10.1200\/JCO.2008.19.8721","volume":"27","author":"HS Friedman","year":"2009","unstructured":"Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T (2009) Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27(28):4733\u20134740","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"5","key":"49_CR14","doi-asserted-by":"publisher","first-page":"740","DOI":"10.1200\/JCO.2008.16.3055","volume":"27","author":"TN Kreisl","year":"2009","unstructured":"Kreisl TN, Kim L, Moore K, Duic P, Royce C, Stroud I, Garren N, Mackey M, Butman JA, Camphausen K, Park J, Albert PS, Fine HA (2009) Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma. J Clin Oncol Off J Am Soc Clin Oncol 27(5):740\u2013745","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"49_CR15","doi-asserted-by":"publisher","first-page":"2484","DOI":"10.1056\/NEJMoa1103799","volume":"365","author":"TJ Perren","year":"2011","unstructured":"Perren TJ, Swart AM, Pfisterer J, Ledermann JA, Pujade-Lauraine E, Kristensen G, Carey MS, Beale P, Cervantes A, Kurzeder C, du Bois A, Sehouli J, Kimmig R, St\u00e4hle A, Collinson F, Essapen S, Gourley C, Lortholary A, Selle F, Mirza MR, Leminen A, Plante M, Stark D, Qian W, Parmar MKB, Oza AM (2011) A phase 3 trial of bevacizumab in ovarian cancer. N Engl J Med 365(26):2484\u20132496","journal-title":"N Engl J Med"},{"issue":"4","key":"49_CR16","doi-asserted-by":"publisher","first-page":"211","DOI":"10.1016\/j.clbc.2011.03.019","volume":"11","author":"A Brufsky","year":"2011","unstructured":"Brufsky A, Hoelzer K, Beck T, Whorf R, Keaton M, Nadella P, Krill-Jackson E, Kroener J, Middleman E, Frontiera M, Paul D, Panella T, Bromund J, Zhao L, Orlando M, Tai F, Marciniak MD, Obasaju C, Hainsworth J (2011) A randomized phase II study of paclitaxel and bevacizumab with and without gemcitabine as first-line treatment for metastatic breast cancer. Clin Breast Cancer 11(4):211\u2013220","journal-title":"Clin Breast Cancer"},{"issue":"30","key":"49_CR17","doi-asserted-by":"publisher","first-page":"3968","DOI":"10.1200\/JCO.2011.36.2236","volume":"29","author":"A Ohtsu","year":"2011","unstructured":"Ohtsu A, Shah MA, Van Cutsem E, Rha SY, Sawaki A, Park SR, Lim HY, Yamada Y, Wu J, Langer B, Starnawski M, Kang Y-K (2011) Bevacizumab in combination with chemotherapy as first-line therapy in advanced gastric cancer: a randomized, double-blind, placebo-controlled phase III study. J Clin Oncol Off J Am Soc Clin Oncol 29(30):3968\u20133976","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"28","key":"49_CR18","doi-asserted-by":"publisher","first-page":"3499","DOI":"10.1200\/JCO.2012.42.8201","volume":"30","author":"E Van Cutsem","year":"2012","unstructured":"Van Cutsem E, Tabernero J, Lakomy R, Prenen H, Prausov\u00e1 J, Macarulla T, Ruff P (2012) Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen. J Clin Oncol Off J Am Soc Clin Oncol 30(28):3499\u20133506","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"49_CR19","unstructured":"\u201cDrugs@FDA: FDA Approved Drug Products,\u201d AFLIBERCEPT"},{"issue":"1","key":"49_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10456-009-9160-6","volume":"13","author":"KJ Gotink","year":"2010","unstructured":"Gotink KJ, Verheul HMW (2010) Anti-angiogenic tyrosine kinase inhibitors: what is their mechanism of action? Angiogenesis 13(1):1\u201314","journal-title":"Angiogenesis"},{"key":"49_CR21","doi-asserted-by":"crossref","unstructured":"Baum CM, Ph D, Figlin RA (2007) N Engl J 115\u2013124","DOI":"10.1080\/07393140601170909"},{"key":"49_CR22","unstructured":"\u201cDrugs@FDA: FDA Approved Drug Products,\u201d SUTENT"},{"issue":"6","key":"49_CR23","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1093\/annonc\/mdm184","volume":"18","author":"O Rixe","year":"2007","unstructured":"Rixe O, Billemont B, Izzedine H (2007) Hypertension as a predictive factor of sunitinib activity. Ann Oncol Off J Eur Soc Med Oncol\/ESMO 18(6):1117","journal-title":"Ann Oncol Off J Eur Soc Med Oncol\/ESMO"},{"issue":"31","key":"49_CR24","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1200\/JCO.2005.03.5881","volume":"23","author":"J Stebbing","year":"2005","unstructured":"Stebbing J, Waters L, Davies L, Mandalia S, Nelson M, Gazzard B, Bower M (2005) Incidence of cancer in individuals receiving chronic zopiclone or eszopiclone requires prospective study. J Clin Oncol Off J Am Soc Clin Oncol 23(31):813","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"10","key":"49_CR25","first-page":"628","volume":"12","author":"A Sulkes","year":"2010","unstructured":"Sulkes A (2010) Novel multitargeted anticancer oral therapies: sunitinib and sorafenib as a paradigm. Isr Med Assoc J IMAJ 12(10):628\u2013632","journal-title":"Isr Med Assoc J IMAJ"},{"issue":"9","key":"49_CR26","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1634\/theoncologist.2008-0131","volume":"13","author":"ME Lacouture","year":"2008","unstructured":"Lacouture ME, Wu S, Robert C, Atkins MB, Kong HH, Guitart J, Garbe C, Hauschild A, Puzanov I, Alexandrescu DT, Anderson RT, Wood L, Dutcher JP (2008) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001\u20131011","journal-title":"Oncologist"},{"issue":"3","key":"49_CR27","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.critrevonc.2010.02.012","volume":"77","author":"FAB Schutz","year":"2011","unstructured":"Schutz FAB, Choueiri TK, Sternberg CN (2011) Pazopanib: clinical development of a potent anti-angiogenic drug. Crit Rev Oncol Hematol 77(3):163\u2013171","journal-title":"Crit Rev Oncol Hematol"},{"issue":"6","key":"49_CR28","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1200\/JCO.2009.23.9764","volume":"28","author":"CN Sternberg","year":"2010","unstructured":"Sternberg CN, Davis ID, Mardiak J, Szczylik C, Lee E, Wagstaff J, Barrios CH, Salman P, Gladkov A, Kavina A, Zarb\u00e1 JJ, Chen M, McCann L, Pandite L, Roychowdhury DF, Hawkins RE (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol Off J Am Soc Clin Oncol 28(6):1061\u20131068","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"12","key":"49_CR29","doi-asserted-by":"publisher","first-page":"4220","DOI":"10.1158\/1078-0432.CCR-08-2740","volume":"15","author":"HI Hurwitz","year":"2009","unstructured":"Hurwitz HI, Dowlati A, Saini S, Savage S, Suttle AB, Gibson DM, Hodge JP, Merkle EM, Pandite L (2009) Phase I trial of pazopanib in patients with advanced cancer. Clin Cancer Res Off J Am Assoc Cancer Res 15(12):4220\u20134227","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"9807","key":"49_CR30","doi-asserted-by":"publisher","first-page":"1931","DOI":"10.1016\/S0140-6736(11)61613-9","volume":"378","author":"BI Rini","year":"2011","unstructured":"Rini BI, Escudier B, Tomczak P, Kaprin A, Szczylik C, Hutson TE, Michaelson MD, Gorbunova VA, Gore ME, Rusakov IG, Negrier S, Ou Y-C, Castellano D, Lim HY, Uemura H, Tarazi J, Cella D, Chen C, Rosbrook B, Kim S, Motzer RJ (2011) Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial. Lancet 378(9807):1931\u20131939","journal-title":"Lancet"},{"issue":"9863","key":"49_CR31","doi-asserted-by":"publisher","first-page":"303","DOI":"10.1016\/S0140-6736(12)61900-X","volume":"381","author":"A Grothey","year":"2013","unstructured":"Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouch\u00e9 O, Mineur L, Barone C, Adenis A, Tabernero J, Yoshino T, Lenz H-J, Goldberg RM, Sargent DJ, Cihon F, Cupit L, Wagner A, Laurent D (2013) Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381(9863):303\u2013312","journal-title":"Lancet"},{"key":"49_CR32","doi-asserted-by":"crossref","unstructured":"Demetri GD, Reichardt P, Kang Y, Blay J, Rutkowski P, Gelderblom H, Hohenberger P, Leahy M, Von Mehren M, Joensuu H, Badalamenti G, Blackstein M, Le Cesne A, Sch\u00f6ff P, Maki RG, Bauer S, Nguyen BB, Xu J, Nishida T, Chung J, Kappeler C, Kuss I, Laurent D, Casali PG Articles efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. 295\u2013302","DOI":"10.1016\/S0140-6736(12)61857-1"},{"key":"49_CR33","unstructured":"\u201cVoice disorders - reflux.\u201d [Online]. Available: http:\/\/www.voicemedicine.com\/reflux.htm. [Accessed: 13-Apr-2013]"},{"issue":"3 Suppl 2","key":"49_CR34","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.otohns.2009.06.744","volume":"141","author":"SR Schwartz","year":"2009","unstructured":"Schwartz SR, Cohen SM, Dailey SH, Rosenfeld RM, Deutsch ES, Gillespie MB, Granieri E, Hapner ER, Kimball CE, Krouse HJ, McMurray JS, Medina S, O\u2019Brien K, Ouellette DR, Messinger-Rapport BJ, Stachler RJ, Strode S, Thompson DM, Stemple JC, Willging JP, Cowley T, McCoy S, Bernad PG, Patel MM (2009) Clinical practice guideline: hoarseness (dysphonia). Otolaryngol Head Neck Surg Off J Am Acad Otolaryngol Head Neck Surg 141(3 Suppl 2):S1\u2013S31","journal-title":"Otolaryngol Head Neck Surg Off J Am Acad Otolaryngol Head Neck Surg"},{"issue":"4","key":"49_CR35","doi-asserted-by":"publisher","first-page":"719","DOI":"10.1016\/S0030-6665(05)70239-5","volume":"33","author":"CB Simpson","year":"2000","unstructured":"Simpson CB, Fleming DJ (2000) Medical and vocal history in the evaluation of dysphonia. Otolaryngol Clin North Am 33(4):719\u2013730","journal-title":"Otolaryngol Clin North Am"},{"issue":"11","key":"49_CR36","doi-asserted-by":"publisher","first-page":"1988","DOI":"10.1097\/01.mlg.0000179174.32345.41","volume":"115","author":"N Roy","year":"2005","unstructured":"Roy N, Merrill RM, Gray SD, Smith EM (2005) Voice disorders in the general population: prevalence, risk factors, and occupational impact. Laryngoscope 115(11):1988\u20131995","journal-title":"Laryngoscope"},{"issue":"5","key":"49_CR37","doi-asserted-by":"publisher","first-page":"953","DOI":"10.1016\/j.otc.2007.05.004","volume":"40","author":"RT Sataloff","year":"2007","unstructured":"Sataloff RT, Hawkshaw MJ, Divi V, Heman-Ackah YD (2007) Physical examination of voice professionals. Otolaryngol Clin North Am 40(5):953\u2013969, v\u2013vi","journal-title":"Otolaryngol Clin North Am"},{"issue":"2","key":"49_CR38","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1177\/000348940611500209","volume":"115","author":"SM Cohen","year":"2006","unstructured":"Cohen SM, Dupont WD, Courey MS (2006) Quality-of-life impact of non-neoplastic voice disorders: a meta-analysis. Ann Otol Rhinol Laryngol 115(2):128\u2013134","journal-title":"Ann Otol Rhinol Laryngol"},{"key":"49_CR39","unstructured":"Services H Common Terminology Criteria for Adverse Events (CTCAE)"},{"issue":"6","key":"49_CR40","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1007\/s10637-009-9314-9","volume":"28","author":"DM Hartl","year":"2010","unstructured":"Hartl DM, Fert\u00e9 C, Loriot Y, Gomez Roca C, Bahleda R, Moldovan C, Mir O, Soria J-C (2010) Dysphonia induced by vascular endothelium growth factor\/vascular endothelium growth factor receptor inhibitors. Invest New Drugs 28(6):884\u2013886","journal-title":"Invest New Drugs"},{"issue":"6","key":"49_CR41","doi-asserted-by":"publisher","first-page":"772","DOI":"10.1038\/sj.bjc.6605828","volume":"103","author":"A Mailliez","year":"2010","unstructured":"Mailliez A, Baldini C, Van JT, Servent V, Mallet Y, Bonneterre J (2010) Nasal septum perforation: a side effect of bevacizumab chemotherapy in breast cancer patients. Br J Cancer 103(6):772\u2013775","journal-title":"Br J Cancer"},{"issue":"9","key":"49_CR42","doi-asserted-by":"publisher","first-page":"3597","DOI":"10.1182\/blood-2002-07-2307","volume":"101","author":"A-M O\u2019Farrell","year":"2003","unstructured":"O\u2019Farrell A-M, Abrams TJ, Yuen HA, Ngai TJ, Louie SG, Yee KWH, Wong LM, Hong W, Lee LB, Town A, Smolich BD, Manning WC, Murray LJ, Heinrich MC, Cherrington JM (2003) SU11248 is a novel FLT3 tyrosine kinase inhibitor with potent activity in vitro and in vivo. Blood 101(9):3597\u20133605","journal-title":"Blood"},{"issue":"1","key":"49_CR43","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1200\/JCO.2005.02.2194","volume":"24","author":"S Faivre","year":"2006","unstructured":"Faivre S, Delbaldo C, Vera K, Robert C, Lozahic S, Lassau N, Bello C, Deprimo S, Brega N, Massimini G, Armand J-P, Scigalla P, Raymond E (2006) Safety, pharmacokinetic, and antitumor activity of SU11248, a novel oral multitarget tyrosine kinase inhibitor, in patients with cancer. J Clin Oncol Off J Am Soc Clin Oncol 24(1):25\u201335","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"49_CR44","doi-asserted-by":"crossref","unstructured":"Wilhelm SM, Carter C, Tang L, Wilkie D, Mcnabola A, Rong H, Chen C, Zhang X, Vincent P, Mchugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA (2004) BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the RAF\/MEK\/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis BAY 43\u20139006 exhibits broad spectrum oral antitumor activity and targets the Pr","DOI":"10.1158\/0008-5472.CAN-04-1443"},{"issue":"24","key":"49_CR45","doi-asserted-by":"publisher","first-page":"11851","DOI":"10.1158\/0008-5472.CAN-06-1377","volume":"66","author":"L Liu","year":"2006","unstructured":"Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, Wilhelm S, Lynch M, Carter C (2006) Sorafenib blocks the RAF\/MEK\/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC\/PRF\/5. Cancer Res 66(24):11851\u201311858","journal-title":"Cancer Res"},{"issue":"1","key":"49_CR46","doi-asserted-by":"publisher","first-page":"66","DOI":"10.1016\/j.ccr.2007.05.006","volume":"12","author":"MS Ricci","year":"2007","unstructured":"Ricci MS, Kim S-H, Ogi K, Plastaras JP, Ling J, Wang W, Jin Z, Liu YY, Dicker DT, Chiao PJ, Flaherty KT, Smith CD, El-Deiry WS (2007) Reduction of TRAIL-induced Mcl-1 and cIAP2 by c-Myc or sorafenib sensitizes resistant human cancer cells to TRAIL-induced death. Cancer Cell 12(1):66\u201380","journal-title":"Cancer Cell"},{"issue":"15","key":"49_CR47","doi-asserted-by":"publisher","first-page":"4632","DOI":"10.1021\/jm800566m","volume":"51","author":"PA Harris","year":"2008","unstructured":"Harris PA, Boloor A, Cheung M, Kumar R, Crosby RM, Davis-Ward RG, Epperly AH, Hinkle KW, Hunter RN, Johnson JH, Knick VB, Laudeman CP, Luttrell DK, Mook RA, Nolte RT, Rudolph SK, Szewczyk JR, Truesdale AT, Veal JM, Wang L, Stafford JA (2008) Discovery of 5-[[4-[(2,3-dimethyl-2H-indazol-6-yl)methylamino]-2-pyrimidinyl]amino]-2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitor. J Med Chem 51(15):4632\u20134640","journal-title":"J Med Chem"},{"issue":"9","key":"49_CR48","doi-asserted-by":"publisher","first-page":"1493","DOI":"10.1002\/jor.22091","volume":"30","author":"S Hosaka","year":"2012","unstructured":"Hosaka S, Horiuchi K, Yoda M, Nakayama R, Tohmonda T, Susa M, Nakamura M, Chiba K, Toyama Y, Morioka H (2012) A novel multi-kinase inhibitor pazopanib suppresses growth of synovial sarcoma cells through inhibition of the PI3K-AKT pathway. J Orthop Res Off Publ Orthop Res Soc 30(9):1493\u20131498","journal-title":"J Orthop Res Off Publ Orthop Res Soc"},{"issue":"8","key":"49_CR49","doi-asserted-by":"publisher","first-page":"1652","DOI":"10.1097\/IAE.0b013e318240a558","volume":"32","author":"M Kernt","year":"2012","unstructured":"Kernt M, Thiele S, Neubauer AS, Koenig S, Hirneiss C, Haritoglou C, Ulbig MW, Kampik A (2012) Inhibitory activity of ranibizumab, sorafenib, and pazopanib on light-induced overexpression of platelet-derived growth factor and vascular endothelial growth factor A and the vascular endothelial growth factor A receptors 1 and 2 and neuropilin 1 and 2. Retina (Philadelphia, PA) 32(8):1652\u20131663","journal-title":"Retina (Philadelphia, PA)"},{"issue":"22","key":"49_CR50","doi-asserted-by":"publisher","first-page":"7272","DOI":"10.1158\/1078-0432.CCR-08-0652","volume":"14","author":"DD Hu-Lowe","year":"2008","unstructured":"Hu-Lowe DD, Zou HY, Grazzini ML, Hallin ME, Wickman GR, Amundson K, Chen JH, Rewolinski DA, Yamazaki S, Wu EY, McTigue MA, Murray BW, Kania RS, O\u2019Connor P, Shalinsky DR, Bender SL (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res Off J Am Assoc Cancer Res 14(22):7272\u20137283","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"},{"issue":"11","key":"49_CR51","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1002\/ijc.25611","volume":"128","author":"J R\u00f6ssler","year":"2011","unstructured":"R\u00f6ssler J, Monnet Y, Farace F, Opolon P, Daudigeos-Dubus E, Bourredjem A, Vassal G, Geoerger B (2011) The selective VEGFR1-3 inhibitor axitinib (AG-013736) shows antitumor activity in human neuroblastoma xenografts. Int J Cancer 128(11):2748\u20132758","journal-title":"Int J Cancer"},{"issue":"1","key":"49_CR52","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ijc.25864","volume":"129","author":"SM Wilhelm","year":"2011","unstructured":"Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Sch\u00fctz G, Thierauch K-H, Zopf D (2011) Regorafenib (BAY 73\u20134506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129(1):245\u2013255","journal-title":"Int J Cancer"},{"issue":"4","key":"49_CR53","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1016\/S0030-6665(05)70243-7","volume":"33","author":"JR Spiegel","year":"2000","unstructured":"Spiegel JR, Hawkshaw M, Sataloff RT (2000) Dysphonia related to medical therapy. Otolaryngol Clin North Am 33(4):771\u2013784","journal-title":"Otolaryngol Clin North Am"},{"issue":"13","key":"49_CR54","doi-asserted-by":"publisher","first-page":"2131","DOI":"10.1200\/JCO.2009.26.3152","volume":"28","author":"JD Hainsworth","year":"2010","unstructured":"Hainsworth JD, Spigel DR, Burris HA, Waterhouse D, Clark BL, Whorf R (2010) Phase II trial of bevacizumab and everolimus in patients with advanced renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 28(13):2131\u20132136","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"49_CR55","doi-asserted-by":"publisher","first-page":"146","DOI":"10.1016\/j.clbc.2011.03.010","volume":"11","author":"DA Yardley","year":"2011","unstructured":"Yardley DA, Burris HA, Clark BL, Shipley D, Rubin M, Barton J, Arrowsmith E, Hainsworth JD (2011) Hormonal therapy plus bevacizumab in postmenopausal patients who have hormone receptor-positive metastatic breast cancer: a phase II Trial of the Sarah Cannon Oncology Research Consortium. Clin Breast Cancer 11(3):146\u2013152","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"49_CR56","doi-asserted-by":"publisher","first-page":"1597","DOI":"10.1007\/s10637-011-9691-8","volume":"30","author":"AH Ko","year":"2012","unstructured":"Ko AH, Youssoufian H, Gurtler J, Dicke K, Kayaleh O, Lenz H-J, Keaton M, Katz T, Ballal S, Rowinsky EK (2012) A phase II randomized study of cetuximab and bevacizumab alone or in combination with gemcitabine as first-line therapy for metastatic pancreatic adenocarcinoma. Invest New Drugs 30(4):1597\u20131606","journal-title":"Invest New Drugs"},{"issue":"5","key":"49_CR57","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1200\/JCO.2008.19.8135","volume":"27","author":"JR Hecht","year":"2009","unstructured":"Hecht JR, Mitchell E, Chidiac T, Scroggin C, Hagenstad C, Spigel D, Marshall J, Cohn A, McCollum D, Stella P, Deeter R, Shahin S, Amado RG (2009) A randomized phase IIIB trial of chemotherapy, bevacizumab, and panitumumab compared with chemotherapy and bevacizumab alone for metastatic colorectal cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(5):672\u2013680","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"key":"49_CR58","doi-asserted-by":"crossref","unstructured":"Vaughan S, Coward JI, Bast RC Jr., Berchuck A, Berek JS, Brenton JD, Coukos G, Crum CC, Drapkin R, Etemadmoghadam D, Friedlander M, Gabra H, Kaye SB, Lord CJ, Lengyel E, Levine DA, Mcneish IA, Stronach EA, Walczak H, Bowtell DD, Balkwill FR (2011) Outcomes 11","DOI":"10.1038\/nrc3144"},{"issue":"12","key":"49_CR59","doi-asserted-by":"publisher","first-page":"1225","DOI":"10.1016\/S1470-2045(12)70509-0","volume":"13","author":"A de Gramont","year":"2012","unstructured":"de Gramont A, Van Cutsem E, Schmoll H-J, Tabernero J, Clarke S, Moore MJ, Cunningham D, Cartwright TH, Hecht JR, Rivera F, Im S-A, Bodoky G, Salazar R, Maindrault-Goebel F, Shacham-Shmueli E, Bajetta E, Makrutzki M, Shang A, Andr\u00e9 T, Hoff PM (2012) Bevacizumab plus oxaliplatin-based chemotherapy as adjuvant treatment for colon cancer (AVANT): a phase 3 randomised controlled trial. Lancet Oncol 13(12):1225\u20131233","journal-title":"Lancet Oncol"},{"key":"49_CR60","unstructured":"Rini BI, Bukowski RM, Curti BD, George DJ, Hudes GR, Redman BG, Margolin KA, Merchan JR, Wilding G, Ginsberg MS, Bacik J, Kim ST (2013) Sunitinib in patients with metastatic. 295(21)"},{"issue":"19","key":"49_CR61","doi-asserted-by":"publisher","first-page":"2154","DOI":"10.1001\/jama.2010.1672","volume":"304","author":"GK Abou-Alfa","year":"2010","unstructured":"Abou-Alfa GK, Johnson P, Knox JJ, Capanu M, Davidenko I, Lacava J, Leung T, Gansukh B, Saltz LB (2010) Doxorubicin plus sorafenib vs doxorubicin alone in patients with advanced hepatocellular carcinoma: a randomized trial. JAMA 304(19):2154\u20132160","journal-title":"JAMA"},{"issue":"26","key":"49_CR62","doi-asserted-by":"publisher","first-page":"4293","DOI":"10.1200\/JCO.2005.01.3441","volume":"24","author":"GK Abou-Alfa","year":"2006","unstructured":"Abou-Alfa GK, Schwartz L, Ricci S, Amadori D, Santoro A, Figer A, De Greve J, Douillard J-Y, Lathia C, Schwartz B, Taylor I, Moscovici M, Saltz LB (2006) Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 24(26):4293\u20134300","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"26","key":"49_CR63","doi-asserted-by":"publisher","first-page":"4274","DOI":"10.1200\/JCO.2009.22.0541","volume":"27","author":"GR Blumenschein","year":"2009","unstructured":"Blumenschein GR, Gatzemeier U, Fossella F, Stewart DJ, Cupit L, Cihon F, O\u2019Leary J, Reck M (2009) Phase II, multicenter, uncontrolled trial of single-agent sorafenib in patients with relapsed or refractory, advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 27(26):4274\u20134280","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"11","key":"49_CR64","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1111\/j.1464-410X.2011.10281.x","volume":"108","author":"S Naito","year":"2011","unstructured":"Naito S, Tsukamoto T, Murai M, Fukino K, Akaza H (2011) Overall survival and good tolerability of long-term use of sorafenib after cytokine treatment: final results of a phase II trial of sorafenib in Japanese patients with metastatic renal cell carcinoma. BJU Int 108(11):1813\u20131819","journal-title":"BJU Int"},{"issue":"11","key":"49_CR65","doi-asserted-by":"publisher","first-page":"1835","DOI":"10.1200\/JCO.2009.26.1321","volume":"28","author":"G Scagliotti","year":"2010","unstructured":"Scagliotti G, Novello S, von Pawel J, Reck M, Pereira JR, Thomas M, Abr\u00e3o Miziara JE, Balint B, De Marinis F, Keller A, Ar\u00e9n O, Csollak M, Albert I, Barrios CH, Grossi F, Krzakowski M, Cupit L, Cihon F, Dimatteo S, Hanna N (2010) Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer. J Clin Oncol Off J Am Soc Clin Oncol 28(11):1835\u20131842","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"3","key":"49_CR66","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1634\/theoncologist.2009-0316","volume":"15","author":"D Koeberle","year":"2010","unstructured":"Koeberle D, Montemurro M, Samaras P, Majno P, Simcock M, Limacher A, Lerch S, Kov\u00e0cs K, Inauen R, Hess V, Saletti P, Borner M, Roth A, Bodoky G (2010) Continuous Sunitinib treatment in patients with advanced hepatocellular carcinoma: a Swiss Group for Clinical Cancer Research (SAKK) and Swiss Association for the Study of the Liver (SASL) multicenter phase II trial (SAKK 77\/06). Oncologist 15(3):285\u2013292","journal-title":"Oncologist"},{"key":"49_CR67","unstructured":"Hilgard P, Gane E, Blanc J, De Oliveira AC, Santoro A, Raoul J, Forner A, Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF, Galle PR, Seitz J, Borbath I, H\u00e4ussinger D, Giannaris T, Sc B, Shan M, Ph D, Moscovici M, Voliotis D, Bruix J (2008) Sorafenib in advanced hepatocellular carcinoma"},{"issue":"14","key":"49_CR68","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/j.ejca.2011.05.007","volume":"47","author":"M Kudo","year":"2011","unstructured":"Kudo M, Imanaka K, Chida N, Nakachi K, Tak W-Y, Takayama T, Yoon J-H, Hori T, Kumada H, Hayashi N, Kaneko S, Tsubouchi H, Suh DJ, Furuse J, Okusaka T, Tanaka K, Matsui O, Wada M, Yamaguchi I, Ohya T, Meinhardt G, Okita K (2011) Phase III study of sorafenib after transarterial chemoembolisation in Japanese and Korean patients with unresectable hepatocellular carcinoma. Eur J Cancer (Oxford, England: 1990) 47(14):2117\u20132127","journal-title":"Eur J Cancer (Oxford, England: 1990)"},{"issue":"1","key":"49_CR69","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1016\/j.ygyno.2010.05.033","volume":"119","author":"M Friedlander","year":"2010","unstructured":"Friedlander M, Hancock KC, Rischin D, Messing MJ, Stringer CA, Matthys GM, Ma B, Hodge JP, Lager JJ (2010) A Phase II, open-label study evaluating pazopanib in patients with recurrent ovarian cancer. Gynecol Oncol 119(1):32\u201337","journal-title":"Gynecol Oncol"},{"issue":"3","key":"49_CR70","doi-asserted-by":"publisher","first-page":"755","DOI":"10.1007\/s10549-012-2399-4","volume":"137","author":"SRD Johnston","year":"2013","unstructured":"Johnston SRD, G\u00f3mez H, Stemmer SM, Richie M, Durante M, Pandite L, Goodman V, Slamon D (2013) A randomized and open-label trial evaluating the addition of pazopanib to lapatinib as first-line therapy in patients with HER2-positive advanced breast cancer. Breast Cancer Res Treat 137(3):755\u2013766","journal-title":"Breast Cancer Res Treat"},{"issue":"3","key":"49_CR71","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1200\/JCO.2008.21.6994","volume":"28","author":"TE Hutson","year":"2010","unstructured":"Hutson TE, Davis ID, Machiels J-PH, De Souza PL, Rottey S, Hong B-F, Epstein RJ, Baker KL, McCann L, Crofts T, Pandite L, Figlin RA (2010) Efficacy and safety of pazopanib in patients with metastatic renal cell carcinoma. J Clin Oncol Off J Am Soc Clin Oncol 28(3):475\u2013480","journal-title":"J Clin Oncol Off J Am Soc Clin Oncol"},{"issue":"9829","key":"49_CR72","doi-asserted-by":"publisher","first-page":"1879","DOI":"10.1016\/S0140-6736(12)60651-5","volume":"379","author":"WTA van der Graaf","year":"2012","unstructured":"van der Graaf WTA, Blay J-Y, Chawla SP, Kim D-W, Bui-Nguyen B, Casali PG, Sch\u00f6ffski P, Aglietta M, Staddon AP, Beppu Y, Le Cesne A, Gelderblom H, Judson IR, Araki N, Ouali M, Marreaud S, Hodge R, Dewji MR, Coens C, Demetri GD, Fletcher CD, Dei Tos AP, Hohenberger P (2012) Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 379(9829):1879\u20131886","journal-title":"Lancet"},{"issue":"4","key":"49_CR73","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1111\/j.1349-7006.2009.01465.x","volume":"101","author":"T Mukohara","year":"2010","unstructured":"Mukohara T, Nakajima H, Mukai H, Nagai S, Itoh K, Umeyama Y, Hashimoto J, Minami H (2010) Effect of axitinib (AG-013736) on fatigue, thyroid-stimulating hormone, and biomarkers: a phase I study in Japanese patients. Cancer Sci 101(4):963\u2013968","journal-title":"Cancer Sci"},{"issue":"9630","key":"49_CR74","doi-asserted-by":"publisher","first-page":"2101","DOI":"10.1016\/S0140-6736(08)60661-3","volume":"371","author":"J-P Spano","year":"2008","unstructured":"Spano J-P, Chodkiewicz C, Maurel J, Wong R, Wasan H, Barone C, L\u00e9tourneau R, Bajetta E, Pithavala Y, Bycott P, Trask P, Liau K, Ricart AD, Kim S, Rixe O (2008) Efficacy of gemcitabine plus axitinib compared with gemcitabine alone in patients with advanced pancreatic cancer: an open-label randomised phase II study. Lancet 371(9630):2101\u20132108","journal-title":"Lancet"},{"issue":"11","key":"49_CR75","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1016\/S1470-2045(07)70285-1","volume":"8","author":"O Rixe","year":"2007","unstructured":"Rixe O, Bukowski RM, Michaelson MD, Wilding G, Hudes GR, Bolte O, Motzer RJ, Bycott P, Liau KF, Freddo J, Trask PC, Kim S, Rini BI (2007) Axitinib treatment in patients with cytokine-refractory metastatic renal-cell cancer: a phase II study. Lancet Oncol 8(11):975\u2013984","journal-title":"Lancet Oncol"},{"issue":"3","key":"49_CR76","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/S1470-2045(11)70004-3","volume":"12","author":"HL Kindler","year":"2011","unstructured":"Kindler HL, Ioka T, Richel DJ, Bennouna J, L\u00e9tourneau R, Okusaka T, Funakoshi A, Furuse J, Park YS, Ohkawa S, Springett GM, Wasan HS, Trask PC, Bycott P, Ricart AD, Kim S, Van Cutsem E (2011) Axitinib plus gemcitabine versus placebo plus gemcitabine in patients with advanced pancreatic adenocarcinoma: a double-blind randomised phase 3 study. Lancet Oncol 12(3):256\u2013262","journal-title":"Lancet Oncol"},{"issue":"9","key":"49_CR77","doi-asserted-by":"publisher","first-page":"2658","DOI":"10.1158\/1078-0432.CCR-11-1900","volume":"18","author":"K Mross","year":"2012","unstructured":"Mross K, Frost A, Steinbild S, Hedbom S, B\u00fcchert M, Fasol U, Unger C, Kr\u00e4tzschmar J, Heinig R, Boix O, Christensen O (2012) A phase I dose-escalation study of regorafenib (BAY 73\u20134506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res Off J Am Assoc Cancer Res 18(9):2658\u20132667","journal-title":"Clin Cancer Res Off J Am Assoc Cancer Res"}],"container-title":["Investigational New Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10637-013-0049-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0049-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10637-013-0049-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,11]],"date-time":"2023-03-11T04:49:31Z","timestamp":1678510171000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10637-013-0049-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,12,18]]},"references-count":77,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,8]]}},"alternative-id":["49"],"URL":"https:\/\/doi.org\/10.1007\/s10637-013-0049-2","relation":{},"ISSN":["0167-6997","1573-0646"],"issn-type":[{"value":"0167-6997","type":"print"},{"value":"1573-0646","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,12,18]]},"assertion":[{"value":"13 August 2013","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 November 2013","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2013","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}